Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Current Assets (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Current Assets for 10 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 53.43% year-over-year to $30.0 million, compared with a TTM value of $30.0 million through Dec 2025, down 53.43%, and an annual FY2025 reading of $30.0 million, down 53.43% over the prior year.
  • Current Assets was $30.0 million for Q4 2025 at VYNE Therapeutics, down from $44.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $143.1 million in Q1 2021 and bottomed at $17.5 million in Q3 2023.
  • Average Current Assets over 5 years is $65.9 million, with a median of $63.2 million recorded in 2021.
  • The sharpest move saw Current Assets plummeted 57.62% in 2022, then skyrocketed 319.94% in 2024.
  • Year by year, Current Assets stood at $63.2 million in 2021, then tumbled by 39.42% to $38.3 million in 2022, then skyrocketed by 150.72% to $96.0 million in 2023, then crashed by 32.85% to $64.4 million in 2024, then plummeted by 53.43% to $30.0 million in 2025.
  • Business Quant data shows Current Assets for VYNE at $30.0 million in Q4 2025, $44.3 million in Q2 2025, and $54.9 million in Q1 2025.